Ready to use single vial docetaxel. Single vial formulation of Docetaxel which not only makes the administration of the drug easier by introducing the premix solution but at the same time provides enhanced safety to patients and para-medical staff. Higher affinity for cancer cell killing as compared to existing Docetaxel. Time taken for onset of action is significantly lesser that of other products , deeper penetration, resulting in greater killing of the cancer cells .


For treatment of different types of cancer, particularly Breast and ovarian cancer. Improved safety as compared to conventional Docetaxel

Product Presentation

20mg/0.5ml, 80mg/2ml, 120mg/3ml, 80mg/4ml ready to use injection.

Unless otherwise specified, all product names appearing in this internet site are trademarks owned by or licensed to VRL India, its subsidiaries or affiliates. No use of any VRL India trademark, trade name, or trade dress in this site may be made without the prior written authorization of VRL India, except to identify the product or services of the company.

Back to Top